1028 related articles for article (PubMed ID: 17004293)
1. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with respiratory syncytial virus vaccines.
Piedra PA
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.
Zeng R; Qi X; Gong W; Mei X; Wei L; Ma C; Yin X
Vaccine; 2007 Oct; 25(42):7422-8. PubMed ID: 17850930
[TBL] [Abstract][Full Text] [Related]
4. The future of respiratory syncytial virus vaccine development.
Polack FP; Karron RA
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
[TBL] [Abstract][Full Text] [Related]
5. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
Shafique M; Wilschut J; de Haan A
Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
[TBL] [Abstract][Full Text] [Related]
6. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
[TBL] [Abstract][Full Text] [Related]
7. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
[TBL] [Abstract][Full Text] [Related]
8. Respiratory syncytial virus and innate immunity: a complex interplay of exploitation and subversion.
Johnson TR
Expert Rev Vaccines; 2006 Jun; 5(3):371-80. PubMed ID: 16827621
[TBL] [Abstract][Full Text] [Related]
9. The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development.
Garg R; Shrivastava P; van Drunen Littel-van den Hurk S
Expert Rev Vaccines; 2012 Dec; 11(12):1441-57. PubMed ID: 23252388
[TBL] [Abstract][Full Text] [Related]
10. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.
Harcourt JL; Karron RA; Tripp RA
J Infect Dis; 2004 Dec; 190(11):1936-40. PubMed ID: 15529257
[TBL] [Abstract][Full Text] [Related]
11. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
Antonis AF; van der Most RG; Suezer Y; Stockhofe-Zurwieden N; Daus F; Sutter G; Schrijver RS
Vaccine; 2007 Jun; 25(25):4818-27. PubMed ID: 17499893
[TBL] [Abstract][Full Text] [Related]
13. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.
Shinoff JJ; O'Brien KL; Thumar B; Shaw JB; Reid R; Hua W; Santosham M; Karron RA
J Infect Dis; 2008 Oct; 198(7):1007-15. PubMed ID: 18702606
[TBL] [Abstract][Full Text] [Related]
14. Involvement of antibody, complement and cellular immunity in the pathogenesis of enhanced respiratory syncytial virus disease.
Delgado MF; Polack FP
Expert Rev Vaccines; 2004 Dec; 3(6):693-700. PubMed ID: 15606354
[TBL] [Abstract][Full Text] [Related]
15. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Munoz FM
Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
[TBL] [Abstract][Full Text] [Related]
16. Basic epidemiology and immunopathology of RSV in children.
Handforth J; Friedland JS; Sharland M
Paediatr Respir Rev; 2000 Sep; 1(3):210-4. PubMed ID: 12531081
[TBL] [Abstract][Full Text] [Related]
17. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
[TBL] [Abstract][Full Text] [Related]
18. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
Huang Y; Cyr SL; Burt DS; Anderson R
J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
[TBL] [Abstract][Full Text] [Related]
19. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.
Kim S; Jang JE; Yu JR; Chang J
Vaccine; 2010 May; 28(22):3801-8. PubMed ID: 20362203
[TBL] [Abstract][Full Text] [Related]
20. Current progress on development of respiratory syncytial virus vaccine.
Chang J
BMB Rep; 2011 Apr; 44(4):232-7. PubMed ID: 21524347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
